LimmaTech Biologics AG
Stefan Herwig is an experienced professional in the field of mass spectrometry and biotherapeutics. Currently serving as the Group Leader Analytics at LimmaTech Biologics AG since January 2018, Stefan oversees the mass spectrometry analytics team and is responsible for analytics and CMC activities related to proprietary biotherapeutics programs, including the development of the CustomGlycan Platform. Prior to this role, Stefan worked as an MS Scientist at LimmaTech Biologics AG from January 2015 to December 2017, focusing on mass spectrometry analysis of glycans, glycoproteins, and glycopeptides. Stefan's academic background includes a PhD from ETH Zurich, where research involved metabolite profiling and data analysis, alongside a Diplom Biologe degree from Johannes Gutenberg University Mainz.
This person is not in any teams
LimmaTech Biologics AG
LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK.